

Table 1.21  
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2017<sup>a</sup>  
Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			25-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 25 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 25 Years <sup>d</sup>
All Sites	Both Sexes	4,694,674	4,862,424	5,368,372	13,765,686	14,245,784
	Male	2,282,549	2,337,240	2,588,177	6,687,937	6,833,302
	Female	2,412,125	2,525,184	2,780,195	7,077,749	7,412,482
Oral Cavity & Pharynx	Both Sexes	120,057	142,267	147,944	299,078	338,743
	Male	86,288	100,445	103,999	207,083	231,393
	Female	33,769	41,822	43,945	91,995	107,350
Esophagus	Both Sexes	21,960	27,475	27,600	38,441	46,212
	Male	17,415	21,514	21,592	30,048	35,800
	Female	4,545	5,961	6,008	8,393	10,412
Stomach	Both Sexes	44,961	54,096	55,059	93,094	108,211
	Male	25,999	31,415	31,852	52,922	61,445
	Female	18,962	22,681	23,207	40,172	46,766
Colon & Rectum	Both Sexes	393,681	454,445	462,550	1,109,412	1,245,698
	Male	204,702	234,601	239,015	566,874	630,738
	Female	188,979	219,844	223,535	542,538	614,960
Liver & Intrahepatic Bile Duct	Both Sexes	51,270	59,777	60,065	76,638	86,978
	Male	36,730	42,403	42,628	54,559	61,209
	Female	14,540	17,374	17,437	22,079	25,769
Pancreas	Both Sexes	46,309	57,798	57,870	62,314	76,239
	Male	23,182	29,094	29,118	30,794	37,899
	Female	23,127	28,704	28,752	31,520	38,340
Larynx	Both Sexes	28,881	34,622	35,074	75,233	86,330
	Male	23,762	28,382	28,753	61,700	70,504
	Female	5,119	6,240	6,321	13,533	15,826
Lung & Bronchus	Both Sexes	235,457	309,793	322,244	404,633	517,130
	Male	106,454	141,260	146,081	176,811	226,337
	Female	129,003	168,533	176,163	227,822	290,793
Melanoma of the Skin	Both Sexes	304,831	357,073	377,941	947,509	1,059,689
	Male	168,743	201,335	215,605	494,706	560,036
	Female	136,088	155,738	162,336	452,803	499,653
Breast	Female	934,184	1,030,280	1,093,384	2,983,076	3,238,158
Cervix	Female	41,009	43,477	43,662	177,813	187,161
Corpus & Uterus, NOS	Female	207,865	233,888	234,170	605,534	669,026
Ovary <sup>f</sup>	Female	62,580	71,602	71,671	163,605	185,902

<sup>a</sup> U.S. 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 registries (not including the Alaska Natives Registry) and 1/1/2017 U.S. population estimates based on the average of 2016 and 2017 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever

<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 25 years (1992-2016)

<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2012-2016)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 25-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2017.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 25-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 25-year limited duration prevalence.

In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

<sup>f</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.21 - continued  
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2017<sup>a</sup>  
 Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			25-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 25 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 25 Years <sup>d</sup>
Prostate	Male	826,957	899,952	900,065	2,947,256	3,135,696
Testis	Male	44,299	45,174	45,735	188,754	192,368
Urinary Bladder	Both Sexes	205,069	259,089	265,383	544,685	650,099
	Male	158,030	199,816	204,940	412,612	491,986
	Female	47,039	59,273	60,443	132,073	158,113
Kidney & Renal Pelvis	Both Sexes	174,099	212,583	216,157	429,086	506,214
	Male	109,433	134,507	136,896	262,352	311,337
	Female	64,666	78,076	79,261	166,734	194,877
Brain & Nervous System	Both Sexes	44,058	47,742	48,179	124,488	130,154
	Male	24,122	26,273	26,512	66,150	69,020
	Female	19,936	21,469	21,667	58,338	61,134
Thyroid	Both Sexes	205,164	231,795	232,442	626,450	686,101
	Male	47,695	56,430	56,607	136,046	153,550
	Female	157,469	175,365	175,835	490,404	532,551
Hodgkin Lymphoma	Both Sexes	35,390	37,895	37,934	146,597	152,671
	Male	19,614	21,106	21,121	77,114	80,200
	Female	15,776	16,789	16,813	69,483	72,471
Non-Hodgkin Lymphoma	Both Sexes	215,280	255,990	261,800	592,703	672,980
	Male	116,184	138,777	141,872	315,105	357,483
	Female	99,096	117,213	119,928	277,598	315,497
Myeloma	Both Sexes	69,911	83,010	83,603	119,296	138,415
	Male	38,921	46,820	47,227	65,614	76,989
	Female	30,990	36,190	36,376	53,682	61,426
Leukemia	Both Sexes	133,638	157,351	157,915	354,813	397,501
	Male	78,659	92,899	93,286	205,064	229,436
	Female	54,979	64,452	64,629	149,749	168,065
Acute Lymphocytic Leukemia	Both Sexes	20,023	20,834	20,842	73,043	74,301
	Male	11,256	11,629	11,629	40,913	41,431
	Female	8,767	9,205	9,213	32,130	32,870
Childhood (Ages 0-19)	Both Sexes	67,519	67,629	68,185	276,483	277,186
	Male	35,671	35,727	36,023	145,459	145,799
	Female	31,848	31,902	32,162	131,024	131,387
Kaposi Sarcoma	Both Sexes	7,443	8,124	8,124	32,836	34,496
	Male	6,804	7,385	7,385	31,200	32,656
	Female	639	739	739	1,636	1,840
Mesothelioma	Both Sexes	3,052	4,124	4,124	4,509	5,804
	Male	2,173	2,902	2,902	2,877	3,706
	Female	879	1,222	1,222	1,632	2,098

<sup>a</sup> U.S. 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 9 registries and 1/1/2017 U.S. population estimates based on the average of 2016 and 2017 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever  
<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 25 years (1992-2016)  
<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2012-2016)  
 For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.  
 In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 25-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2017.  
 In method (d) the 1981 melanoma is counted for the melanoma and all sites 25-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 25-year limited duration prevalence.  
 In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.